[2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis]

Area of Science:

• Rheumatology
• Clinical Guideline Development
• Evidence-Based Medicine

Background:

• Rheumatoid arthritis (RA) poses a significant health challenge in China.
• Existing diagnostic and treatment protocols require updates based on current evidence.
• A need exists for a standardized, evidence-based approach tailored to the Chinese population.

Purpose of the Study:

• To develop a comprehensive, evidence-based guideline for the diagnosis and treatment of rheumatoid arthritis (RA) in China.
• To provide clinicians and patients with a decision-making tool for optimal RA management.
• To incorporate the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for robust recommendations.

Main Methods:

• A multidisciplinary guideline development group was formed.
• The GRADE system was employed to assess the quality of evidence and strength of recommendations.
• Recommendations were formulated considering evidence, benefit-harm balance, and patient values.

Main Results:

• Ten key recommendations for RA diagnosis and treatment were developed.
• The guideline encompasses classification criteria, disease activity monitoring, and assessment.
• It details the use of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids within a treat-to-target framework.

Conclusions:

• This guideline offers a standardized, evidence-based approach to RA management in China.
• It aims to improve clinical decision-making for healthcare providers and patients.
• The guideline promotes the treat-to-target strategy for better RA outcomes.